Derivation of the sledai. A disease activity index for lupus patients
1992/06/01 by Claire Bombardier, Dafna D. Gladman, Murray B. Urowitz +26 · 41 citations
Medicine · #Systemic Lupus Erythematosus Research #Musculoskeletal Disorders and Rehabilitation #Rheumatoid Arthritis Research and Therapies
paper · doi:10.1002/art.1780350606
Abstract
OBJECTIVE: To standardize outcome measures in systemic lupus erythematosus (SLE). Three indices were identified which could adequately describe outcome (disease activity, damage from disease, and health status); we describe here the development of the Disease Activity Index. METHODS: Twenty-four variables were identified as important factors in a disease activity index. These were used to generate 574 patient profiles, which were rated on a disease activity scale of 0-10 by 14 rheumatologists. A second rating of 10 of the profiles yielded scores that were not significantly different from the first, indicating that experienced clinicians can reliably make global estimates of disease activity. Multiple regression models were used to estimate the relative importance of the 24 clinical variables in the physicians' global rating of disease activity. These were estimated on a "training set" of 75% of physicians' ratings, and then validated on a "testing set," consisting of the remaining 25% of physicians' ratings. RESULTS: The explanatory power of the models in the training set was high (R2 = 0.93). The models' regression coefficients for the organ systems were simplified for easier use in clinical practice. This generated a "weighted" index of 9 organ systems for disease activity in SLE, the SLEDAI, as follows: 8 for central nervous system and vascular, 4 for renal and musculoskeletal, 2 for serosal, dermal, immunologic, and 1 for constitutional and hematologic. The maximum theoretical score is 105, but in practice, few patients have scores greater than 45. The SLEDAI predicted well the physicians' ratings in the testing set (Pearson's correlation coefficients = 0.64-0.79). CONCLUSION: The SLEDAI is a validated model of experienced clinicians' global assessments of disease activity in lupus. It represents the consensus of a group of experts in the field of lupus research.
Cited by
- The reliability of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index in patients with Systemic Lupus Erythematosus
- Expansion of circulating T cells resembling follicular helper T cells is a fixed phenotype that identifies a subset of severe systemic lupus erythematosus
- Complement Alternative Pathway׳s Activation in Patients With Lupus Nephritis
- Increased apoptotic neutrophils and macrophages and impaired macrophage phagocytic clearance of apoptotic neutrophils in systemic lupus erythematosus
- Network analysis of associations between serum interferon‐α activity, autoantibodies, and clinical features in systemic lupus erythematosus
- Sialic acid–binding Ig‐like lectin 1 expression in inflammatory and resident monocytes is a potential biomarker for monitoring disease activity and success of therapy in systemic lupus erythematosus
- B Cell Activation and Plasma Cell Differentiation Are Promoted by IFN-λ in Systemic Lupus Erythematosus
- Risk Factors for Symptomatic Avascular Necrosis in Childhood-onset Systemic Lupus Erythematosus
- Chronic Inflammatory Disease Is an Independent Risk Factor for Coronary Flow Velocity Reserve Impairment Unrelated to the Processes of Coronary Artery Calcium Deposition
- Development and Initial Validation of the Systemic Lupus Erythematosus Disease Activity Index 2000 Responder Index 50
- Diverse antiphospholipid syndromes and beyond: A multicenter comprehensive analysis from the Egyptian College of Rheumatology
- Clinical characteristics and risk factors for lupus flares in sub-Saharan Africa-retrospective cross-sectional study
- Haematopoietic SCT in severe autoimmune diseases: updated guidelines of the European Group for Blood and Marrow Transplantation
- B cell-targeted therapies in systemic lupus erythematosus
- Distance-Correlation based Gene Set Analysis in Longitudinal Studies
- Efficacy and safety of dapagliflozin in inactive lupus nephritis: a randomized crossover trial
- Mitochondrial hyperpolarization and ATP depletion in patients with systemic lupus erythematosus. [europepmc]
- Rapamycin reduces disease activity and normalizes T cell activation-induced calcium fluxing in patients with systemic lupus erythematosus. [europepmc]
- A modular analysis framework for blood genomics studies: application to systemic lupus erythematosus. [europepmc]
- Activation of mammalian target of rapamycin controls the loss of TCRzeta in lupus T cells through HRES-1/Rab4-regulated lysosomal degradation. [europepmc]
- Prospective analysis of neuropsychiatric events in an international disease inception cohort of patients with systemic lupus erythematosus. [europepmc]
- EULAR Sjogren's syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjogren's syndrome. [europepmc]
- Novel evidence-based systemic lupus erythematosus responder index. [europepmc]
- Interferon-regulated chemokines as biomarkers of systemic lupus erythematosus disease activity: a validation study. [europepmc]
- Increased levels of circulating microparticles in primary Sjögren's syndrome, systemic lupus erythematosus and rheumatoid arthritis and relation with disease activity. [europepmc]
- A distinct subset of proinflammatory neutrophils isolated from patients with systemic lupus erythematosus induces vascular damage and synthesizes type I IFNs. [europepmc]
- Dysregulated balance of Th17 and Th1 cells in systemic lupus erythematosus. [europepmc]
- A systematic review and meta-analysis of pregnancy outcomes in patients with systemic lupus erythematosus and lupus nephritis. [europepmc]
- Netting neutrophils induce endothelial damage, infiltrate tissues, and expose immunostimulatory molecules in systemic lupus erythematosus. [europepmc]
- N-acetylcysteine reduces disease activity by blocking mammalian target of rapamycin in T cells from systemic lupus erythematosus patients: a randomized, double-blind, placebo-controlled trial. [europepmc]
- Hydroxychloroquine is associated with impaired interferon-alpha and tumor necrosis factor-alpha production by plasmacytoid dendritic cells in systemic lupus erythematosus. [europepmc]
- Circulating microRNA expression profiles associated with systemic lupus erythematosus. [europepmc]
- Allogeneic mesenchymal stem cell transplantation in severe and refractory systemic lupus erythematosus: 4 years of experience. [europepmc]
- Population-based incidence and prevalence of systemic lupus erythematosus: the Michigan Lupus Epidemiology and Surveillance program. [europepmc]
- Measuring therapeutic response in chronic graft-versus-host disease. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: IV. The 2014 Response Criteria Working Group report. [europepmc]
- EULAR Sjögren's syndrome disease activity index (ESSDAI): a user guide. [europepmc]
- Personalized Immunomonitoring Uncovers Molecular Networks that Stratify Lupus Patients. [europepmc]
- Sirolimus in patients with clinically active systemic lupus erythematosus resistant to, or intolerant of, conventional medications: a single-arm, open-label, phase 1/2 trial. [europepmc]
- CD38 Is Robustly Induced in Human Macrophages and Monocytes in Inflammatory Conditions. [europepmc]
- High levels of circulating interferons type I, type II and type III associate with distinct clinical features of active systemic lupus erythematosus. [europepmc]
- New insights into the role of antinuclear antibodies in systemic lupus erythematosus. [europepmc]
Related